Ratings biote Corp.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
5.75 ^USD	-1.54%		-8.00%	+16.40%

May. 10	Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	CI
May. 07	Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	MT

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company has a low valuation given the cash flows generated by its activity.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOTE CORP.	+16.40%	168M		-
CENGAGE LEARNING HOLDINGS II, INC.	+35.90%	828M	-	D
CHEGG, INC.	-61.44%	470M		C
NIIT LIMITED	-8.91%	166M		C
DAEKYO CO., LTD.	0.00%	145M		-
FLOWSPARKS N.V.	0.00%	53.88M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality